What Are the Fundamentals Of RMD?

Large-cap Health Care company ResMed has moved -0.5% so far today on a volume of 69,973, compared to its average of 1,666,859. In contrast, the S&P 500 index moved -1.0%.

ResMed trades -23.05% away from its average analyst target price of $184.0 per share. The 8 analysts following the stock have set target prices ranging from $165.0 to $220.0, and on average have given ResMed a rating of buy.

If you are considering an investment in RMD, you'll want to know the following:

  • ResMed's current price is 128.0% above its Graham number of $62.1, which implies that at its current valuation it does not offer a margin of safety

  • ResMed has moved -39.0% over the last year, and the S&P 500 logged a change of 11.0%

  • Based on its trailing earnings per share of 6.09, ResMed has a trailing 12 month Price to Earnings (P/E) ratio of 23.2 while the S&P 500 average is 15.97

  • RMD has a forward P/E ratio of 18.3 based on its forward 12 month price to earnings (EPS) of $7.75 per share

  • The company has a price to earnings growth (PEG) ratio of 1.78 — a number near or below 1 signifying that ResMed is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 5.04 compared to its sector average of 4.16

  • ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.

  • Based in San Diego, the company has 10,140 full time employees and a market cap of $20.83 Billion. ResMed currently returns an annual dividend yield of 1.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.